I About
Iambic Therapeutics develops AI-powered platforms for de novo drug design, focusing on challenging targets with unmet medical needs. Their core technology combines multimodal transformers and protein co-folding AI – specifically “Enchant” and “NeuralPLexer” – with a high-throughput experimental platform to rapidly iterate between molecular design and biological validation. Founded in 2019, Iambic aims to deliver diverse, high-quality drug leads by exploring novel mechanisms of action within vast chemical spaces.
Focus Areas
Technology Focus
drug discovery healthcare ai
Quick Stats
- Founded
- 2019
- Status
- private
- Type
- startup
Explore More
Similar Companies
Ranked by shared focus areas, technology, and location.
Xaira Therapeutics
San Francisco, United States
100%
2 shared categories
2 shared AI types
Same country
Drug DiscoveryHealthcare AI
Verge Genomics
San Francisco, United States
100%
2 shared categories
2 shared AI types
Same country
Drug DiscoveryHealthcare AI
BPGbio
Framingham, United States
100%
2 shared categories
2 shared AI types
Same country
Drug DiscoveryHealthcare AI
Terray Therapeutics
Pasadena, United States
100%
2 shared categories
2 shared AI types
Same country
Drug DiscoveryHealthcare AI